annb0t
Top 20
Indaptus Therapeutics INDP announced positive data from pre-clinical studies that demonstrated the efficacy of Decoy, its bacteria-based immunotherapy platform technology. The data was presented in a
poster at the American Association for Cancer Research (AACR) annual scientific conference. The poster was on a previous generation drug, Decoy10, from the companyâs proprietary Decoy anti-tumor platform. The stock of the company climbed 22% on Wednesday, following the encouraging news.
In th...
>>> Read more: Indaptus (INDP) Surges on Upbeat Pre-Clinical Decoy Data
poster at the American Association for Cancer Research (AACR) annual scientific conference. The poster was on a previous generation drug, Decoy10, from the companyâs proprietary Decoy anti-tumor platform. The stock of the company climbed 22% on Wednesday, following the encouraging news.
In th...
>>> Read more: Indaptus (INDP) Surges on Upbeat Pre-Clinical Decoy Data
